Close this search box.

Deals roundup: Novo-EraCal in second obesity deal, Roche gives back Hookipa’s HB-700, and more


BioCentury’s weekly roundup of biopharma deals, Jan. 23-29

By Gunjan Ohri, Data Content Analyst

January 30, 2024 1:24 AM UTC

Beyond last week’s headline deal — the $2.2 billion agreement through which Sanofi (Euronext:SAN; NASDAQ:SNY) gained INBRX-101 from Inhibrx Inc. (NASDAQ:INBX) — a handful of other transactions also rose above the noise.

In the red-hot obesity space, a 2022 research collaboration between Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) and Swiss biotech  EraCal Therapeutics Ltd. to identify molecules using EraCal’s zebrafish larvae platform has given rise to a second deal between the two companies, this time a licensing agreement centered on the development of an oral small molecule that controls appetite and body weight. EraCal is eligible for up to $256 million in an upfront payment of undisclosed size and milestones, plus sales royalties.